Brussels, 2 April 2026
Almost 40 European, national and regional industry organisations, including Cofalec, have united to reinforce the critical importance of the Biotech Act II. A joint position paper highlights the need for a dedicated and globally ambitious legislation to deliver biomanufacturing scale‑up and market deployment in Europe.
Europe remains the only major global region without a dedicated biomanufacturing initiative. At a time when global competitors such as the United States, India and China are prioritising biomanufacturing at the highest strategic level, the signatories call for a growth and market‑focused EU Biotech Act II to strengthen competitiveness, resilient value chains and high‑quality employment across Europe.
Actions, including the EU Biotech Act Part I which primarily targets health, have boosted innovation, but a critical gap persists in translating innovation into industrial scale in all sectors.
Signatories will continue to work together to support a shared vision for Europe’s industrial future and to ensure that biomanufacturing plays its full role in delivering long‑term growth and resilience.